Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Costantino Zampaletta
Observed names:
C Zampaletta,
C. Zampaletta,
Zampaletta, C.,
Zampaletta, Costantino
Institution:
Ospedale di Belcolle
Observed institutions:
University of Parma,
Azienda Sanitaria Locale Viterbo,
Ospedale Cristo Re,
Ospedale di Belcolle,
Ospedale L. Bonomo
OpenAlex ID:
A5018440651
Development and Validation of an Endoscopic Classification of Diverticular Disease of the Colon: The DICA Classification
2014
·
Antonio Tursi
, Giovanni Brandimarte
, et al.
·
Digestive Diseases
·
95
Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study
2015
·
Antonio Tursi
, Giovanni Brandimarte
, et al.
·
United European Gastroenterology Journal
·
58
Lansoprazole-induced microscopic colitis: An increasing problem? Results of a prospecive case-series and systematic review of the literature
2010
·
Gabriele Capurso
, Massimo Marignani
, et al.
·
Digestive and Liver Disease
·
49
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients
2021
·
Antonio Tursi
, Giammarco Mocci
, et al.
·
European Journal of Gastroenterology & Hepatology
·
45
Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn’s disease: an open-label, pilot study
2014
·
A. Tursi
, W. Elisei
, et al.
·
Techniques in Coloproctology
·
42
Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study
2021
·
Antonio Tursi
, Giovanni Brandimarte
, et al.
·
Gut
·
38
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
2022
·
Antonio Tursi
, Giammarco Mocci
, et al.
·
Inflammatory Bowel Diseases
·
37
Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers
2017
·
Antonio Tursi
, Leonardo Allegretta
, et al.
·
Journal of Gastrointestinal and Liver Diseases
·
31
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers
2018
·
Antonio Tursi
, Walter Elisei
, et al.
·
Medicine
·
29
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers
2019
·
Antonio Tursi
, Giammarco Mocci
, et al.
·
European Journal of Internal Medicine
·
28
Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres
2014
·
Antonio Tursi
, Walter Elisei
, et al.
·
European Journal of Internal Medicine
·
26
Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy.
2014
·
Antonio Tursi
, Walter Elisei
, et al.
·
PubMed Central
·
24
PDF
Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study.
2021
·
A Tursi
, G Mocci
, et al.
·
PubMed
·
23
Managing ambulatory ulcerative colitis patients with infliximab: A long-term follow-up study in primary gastroenterology centers
2014
·
Antonio Tursi
, Walter Elisei
, et al.
·
European Journal of Internal Medicine
·
19
Helicobacter pyloriInfection: Is Sequential Therapy Superior to Standard Triple Therapy? A Single-Centre Italian Study in Treatment-Naive and Non-Treatment-Naive Patients
2011
·
R Urgesi
, G Pelecca
, et al.
·
Canadian Journal of Gastroenterology
·
18
PDF
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis
2023
·
Antonio Tursi
, Daniele Piovani
, et al.
·
The American Journal of Gastroenterology
·
17
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
2022
·
Antonio Tursi
, Giammarco Mocci
, et al.
·
Journal of Gastrointestinal and Liver Diseases
·
16
PDF
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
2024
·
Antonio Tursi
, Giammarco Mocci
, et al.
·
Expert Opinion on Biological Therapy
·
14
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis
2023
·
Antonio Tursi
, Daniele Piovani
, et al.
·
United European Gastroenterology Journal
·
14
PDF
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study
2023
·
Giammarco Mocci
, Antonio Tursi
, et al.
·
Expert Opinion on Biological Therapy
·
14
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
2023
·
Antonio Tursi
, Giammarco Mocci
, et al.
·
Expert Opinion on Pharmacotherapy
·
13
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
2022
·
Giammarco Mocci
, Giorgia Bodini
, et al.
·
Biomedicines
·
13
PDF
Spontaneous right ventricular thrombus in a patient with active ulcerative colitis and protein C deficiency: a review with a case report.
2010
·
R Urgesi
, C Zampaletta
, et al.
·
PubMed
·
12
Long-Term Effectiveness and Safety of Ustekinumab in Crohn’s Disease: Results from a Large Real-Life Cohort Study
2024
·
Giammarco Mocci
, Antonio Tursi
, et al.
·
Journal of Clinical Medicine
·
10
PDF
Vitamin D Signaling in Gastro-Rheumatology: From Immuno-Modulation to Potential Clinical Applications
2021
·
Cristiano Pagnini
, Andrea Picchianti-Diamanti
, et al.
·
International Journal of Molecular Sciences
·
10
PDF
Show more works
View as search
Works count:
67
Citation count:
747
H-index:
16
I10-index:
25
Year
Topic
Type